Skip to content
Back to glossary
Therapeutics

BPC-157

BPC-157 is a synthetic 15-amino-acid peptide. It is based on a sequence found in human gastric juice. It is marketed for healing your tendons, ligaments, and gut. Animal studies hint at pro-angiogenic (blood-vessel-growing) and tissue-repair effects. But the human trial data are very limited, just a few small pilot studies, with no large, well-controlled RCTs. It is not approved by the FDA or EMA. Injectable BPC-157 was placed on the FDA's 503A Category 2 list (significant safety concerns), among interim bulk drug substances. It was removed from Category 2 on 22 April 2026, alongside eleven other peptides whose nominators withdrew. A Pharmacy Compounding Advisory Committee (PCAC) review is scheduled for 23 to 24 July 2026. But that is not an approval. BPC-157 stays unauthorized for any therapeutic use. And it is banned at all times under WADA category S0 (Unapproved Substances).

Last reviewed:

This definition is educational and is not medical advice, a diagnosis, or treatment. Talk to a doctor about any health decisions. Read our full medical disclaimer

Sources

  1. Sikiric P, Seiwerth S, Grabarevic Z et al. (1999). The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacologydoi:10.1007/s10787-999-0022-z
  2. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journaldoi:10.1177/15563316251355551

Used in